Is It Time to Buy These 2 Cancer-Fighting Companies?

Seattle Genetics' (SGEN) and Pharmacyclics' (PCYC) shares are tumbling, despite promising cancer drugs that could see significant sales growth.

Mar 27, 2014 at 5:41PM

Investors shouldn't buy and sell shares on market whims and whispers. After all, markets can jump up and down when we least expect it, and that means the chances for predicting its direction over a short period of time is a coin flip, at best.

Instead, investors should take a long-term view when evaluating companies, and consider whether these companies have a competitive advantage that can be leveraged for market share and shareholder-friendly profit.

Using that approach can turn investors on to exciting new companies that are innovating, and give investors a chance to take advantage of the market's inevitable drops to buy for the long haul. Given that backdrop, investors may want to turn their attention to Seattle Genetics (NASDAQ:SGEN) and Phamacyclics (NASDAQ:PCYC), two biotechnology companies with impressive cancer-fighting therapies.

SGEN Chart

SGEN data by YCharts

1. Seattle Genetics
Seattle Genetics has one currently marketed drug: Adcetris. Adcetris is a treatment for lymphoma that won FDA approval in 2011, and generated nearly $145 million in sales last year. Normally, a drug with $145 million in sales wouldn't be overly exciting. However, it's Adcetris' potential for label expansion that makes it so intriguing.

Adcetris is currently approved as a treatment for relapsing, post chemotherapy Hodgkin's lymphoma, or HL, patients. It's also approved as a second-line treatment for anaplastic large-cell lymphoma, or ALCL. The drug has already captured 70% of those markets, but expanding its use in Hodgkins' from a third-line therapy to second-line one would significantly boost its addressable market.

In addition to the opportunity to expand Adcetris' use in HL, Seattle is also studying Adcetris in large B-cell lymphoma, or DLBCL, for which the company received FDA orphan designation last year, as a frontline drug for mature T-cell lymphoma, or MTCL, and relapsed cutaneous T-cell lymphoma, or CTCL. Across its various potential indications, Seattle estimates Adcetris could be a $1 billion-a-year drug.

That alone could make for a compelling argument for owning Seattle's shares, but a much larger market may exist in leveraging the company's antibody drug conjugate, or ADC, technology that delivers Adcetris to its target.

AbbVie has already expanded its agreement with Seattle for use of that ADC technology twice since 2011, including in January when it agreed to pay Seattle up to $255 million per research target for therapies successfully incorporating it. Last summer, Bayer inked a similar deal with Seattle, agreeing to pay up to $500 million in milestones for treatments using Seattle's ADCs.

2. Pharmacyclics
Much like Seattle, Pharmacyclics has an impressive cancer-fighting drug in Imbruvica that has big time potential to treat a variety of indications. The company co-developed Imbruvica with Johnson & Johnson (NYSE:JNJ), and Johnson has been so convinced by Imbruvica's potential that it's already handed over $385 million in milestone payments to Pharmacyclics, including $110 million in the fourth quarter alone.

Currently, Imbruvica is approved as a second line therapy to treat mantle cell leukemia, or MCL, and chronic lymphocytic leukemia, or CLL. The standard of care for CLL patients is chemotherapy and immunotherapy. However, studies suggest Imbruvica could someday replace side-affect laden chemotherapy in those patients.

In addition to its potential in CLL, Pharmacyclics and Johnson are also studying Imbruvica's use in large B-cell lymphoma, multiple myeloma, follicular lymphoma, which is a common form of intolerant non-Hodgkins, and Waldenstrom's, which is a less common non-Hodgkin's lymphoma. That potential to significantly expand Imbruvica's label has Industry analysts thinking the drug could someday hit peak annual sales of $6 billion.

Fool-worthy final thoughts
It's hard to make an argument that shares in either company are inexpensive, given that Adcetris is Seattle's only marketed drug, and the company's current $5.6 billion market cap dwarfs Adcetris' current sales. Similarly, Pharmacyclics' $7.9 billion market cap is pretty heady if you're only looking at the $410 million Wall Street currently expects in revenue this year.

That said, both of these companies have irons in the fire and competitive advantages that may warrant a premium valuation, because they may drive sales significantly higher. That potential for growth is a key reason why shares in both companies were hitting new highs at the end of February. Shares in Seattle have dropped 13% and Pharmacyclics' shares have slumped more than 20% since then. That may suggest it's a good time for speculative growth investors to consider these two for the long term.

Here's one more stock you really ought to know about
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free, and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

 

Todd Campbell is long Seattle Genetics. Todd owns institutional research firm E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not own shares in the companies mentioned. The Motley Fool recommends Johnson & Johnson and Seattle Genetics. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers